Early Detection and Intervention for Women At-risk of Psychosis
- Conditions
- Prodromal Schizophrenia
- Registration Number
- NCT03751865
- Lead Sponsor
- The University of Hong Kong
- Brief Summary
This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.
- Detailed Description
Eligible subjects with informed consent provided will be randomly assigned to the cognitive behavioural therapy (CBT) group or psychoeducation group. Each group consists of 8 session spanning for 8 week.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 160
- women of age 18-64
- at-risk mental state as defined by the Comprehensive Assessment of At-Risk Mental States (CAARMS)
- with an informed consent
- able to understand Cantonese and read/write Chinese
- those mental conditions that requires other treatment priorities (e.g., suicidal risk, substance abuse, current or past episodes of psychotic disorder, personality disorders)
- those medical conditions that severely limits participation, comprehension, or adherence to the treatment (e.g., epilepsy, dementia, terminal medical illness);
- those who are receiving structured psychotherapy or counselling
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Conversion of psychosis 12-month post-intervention Proportion of subject that convert from at-risk state to psychosis
Functioning: Measured by Role Functioning Scale (RFS) Changes from baseline to immediate, 6- and 12-month post-intervention Measured by Role Functioning Scale (RFS). The RFS is comprised of four single rating scaled for evaluating the functioning of individuals in specified areas of everyday life. The four role functions assessed are:(1)Working: productivity, (2) Independent living and self care, (3) Immediate social network relationships, and (4) Extended social network relationship. The values on each of the four scales range from 1 (minimal level of role functioning), to 7 (hypothetically optimal level of role functioning). Each of the seven points on the scales is accompanied by a behaviorally defined description.
Functioning: Measured by Social and Occupational Functioning Assessment Scale (SOFAS) Changes from baseline to immediate, 6- and 12-month post-intervention Measured by Social and Occupational Functioning Assessment Scale (SOFAS). The SOFAS is an observer rating scale. Ratings should be based on subject's behavior during the last 1 month. The score ranges from 0-100. A higher score represents a better outcome.
- Secondary Outcome Measures
Name Time Method Social anxiety :Measured by Liebowitz Social Anxiety Scale (LSAS) Immediate, 6- and 12-month post-intervention Measured by Liebowitz Social Anxiety Scale (LSAS). The LSAS consists of 24 questions, the rater has to rate from 0-3 in Fear or Anxiety domain or Avoidance domain for each of the 24 questions. The higher score represents more severe social anxiety.
Depressive symptoms Immediate, 6- and 12-month post-intervention Measured by the Calgary Depression Scale for Schizophrenia (CDSS). The scale consists of 9 questions, each has the response ranging from 0 to 3. The higher score presents more severe depressive symptoms.
Positive psychotic symptoms Immediate, 6- and 12-month post-intervention Measurement of positive symptoms using the Chinese version of the Psychotic Symptom Rating Scales (C-PSYRATS). It comprises of the auditory hallucinations (AHS) and delusions subscales (DS). The AHS has 11 questions and the DS consists of 6 questions, each question has the responses ranging from 0-4. The higher score represents more severe positive psychotic symptoms.
Beliefs about the auditory hallucination Immediate, 6- and 12-month post-intervention Measured by the Beliefs About Voices Questionnaire (BAVQ-R). The BAVQ-R has 35 questions, the 4 responses range from disagree, unsure, slightly agree to strongly agree. The higher score represents more convicted belief about the voices.
Trial Locations
- Locations (1)
University of Hong Kong
🇭🇰Hong Kong, Hong Kong
University of Hong Kong🇭🇰Hong Kong, Hong KongYi Nam SuenContact